OBJECTIVES: Lung cancer poses a considerable disease and economic burden on healthcare systems globally. Alectinib, a highly selective, CNS-active anaplastic lymphoma kinase (ALK) inhibitoris a new treatment option for 5% of Non-Small Cell Lung Cancer (NSCLC) patients who carry mutations associated with ALK. The objective of this analysis is to estimate the potential budgetary impact of the introduction of Alectinib as a 1^st line treatment approach in ALK+ NSCLC patients in the Greek healthcare setting.

METHODS: The analysis was based on a budget impact model considering the market shares and price of Alectinib as a 1^st line treatment approach in ALK+ NSCLC patients compared to Crizotinib, Ceritinib and chemotherapy. The model was populated with epidemiological and clinical effectiveness data from the literature and Greek-specific inputs on health resource use, based on an expert panel of 10 oncologists. The analysis followed a third party payer perspective (Greek Social Insurance).

RESULTS: CONCLUSIONS: Based on the available epidemiological data for Greece, 5100 patients are diagnosed with NSCLC, of which 109 are eligible for treatment with an ALK inhibitor such as Alectinib. Owing mostly to the small number of patients, the budget impact of the introduction of Alectinib is reasonable.